2016-03-14T00:00:00.000-04:00
gynecologic diseases,-0.577521
Equal Weight,-0.517209
Novo Nordisk,0.60274
Buy rating,0.213883
stress urinary incontinence,-0.424095
heart failure signal,-0.266818
Market Perform,-0.479017
UBS,0.161086
Antero Midstream,-0.335266
new treatments,-0.577521
price target,0.213883
Energy Transfer Equity,0.295946
SAVOR outcome trial,-0.266818
Energy Transfer Partners,0.343153
new long-term targets,0.60274
David Socks,0.346514
biopharmaceutical company,-0.577521
stock price,0.499876
Buy,-0.231202
MKM Partners,-0.424828
Outperform,-0.426325
Frazier Healthcare Partners,0.215562
exceptional asset,0.56348
Neutral,-0.425577
Novo A/S,0.215562
Outpost Medicine,0.56348
Baird,-0.423989
Keefe Bruyette,-0.495948
Morgan Stanley,-0.513334
great entry point,0.499876
interim CEO,0.45436
Conviction Buy,-0.539172
clinical-stage product candidate,-0.424095
